Who are the top shareholders of the Kerala Ayurveda?

The top shareholders of Kerala Ayurveda are Katra Holdings Ltd with 53.97%, followed by individual investors at 32.23%, and Porinju Veliyath as the largest public shareholder at 5.18%. Mutual funds hold 0.02%, and there are no foreign institutional investors.

The top shareholders of Kerala Ayurveda include Katra Holdings Ltd, which holds the largest share at 53.97%. This is followed by individual investors, who collectively own 32.23% of the company. The highest public shareholder is Porinju Veliyath, with a holding of 5.18%. Additionally, there is a small percentage of shares held by mutual funds, specifically 0.02%, and no foreign institutional investors (FIIs) currently hold shares in the company.

Who are in the management team of Kerala Ayurveda?

As of March 2022, the management team of Kerala Ayurveda includes Ramesh Vangal (Chairman), K Anilkumar (Whole-time Director), Anand Subramanian, Gokul Patnaik, and several independent directors, along with Ashitha B R as Company Secretary.

As of March 2022, the management team of Kerala Ayurveda includes the following individuals:<BR><BR>1. Ramesh Vangal - Chairman (Non-Executive)<BR>2. K Anilkumar - Whole-time Director<BR>3. Anand Subramanian - Director<BR>4. Harish Menon - Independent Director<BR>5. Gokul Patnaik - Director<BR>6. S Krishnamurthy - Independent Director<BR>7. Ashitha B R - Company Secretary & Compliance Officer<BR>8. Shilpa Kiran Gududur - Independent Director<BR>9. Rajesh Sharma - Independent Director<BR><BR>These members play various roles in the governance and management of the company.

What does Kerala Ayurveda do?

Kerala Ayurveda Ltd manufactures Ayurveda products and operates in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of 31 Cr and a net loss of 16 Cr, with a market cap of Rs 547 Cr.

Overview: <BR>Kerala Ayurveda Ltd is engaged in the manufacture of Ayurveda products and operates within the Pharmaceuticals & Biotechnology industry, classified as a Micro Cap company.<BR><BR>History: <BR>Kerala Ayurveda Ltd was established on 6th July 1992. The company has recently reported net sales and profit for the quarter ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 31 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -16 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 547 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 7.09 <BR>Return on Equity: -154.90% <BR>Price to Book: 57.69<BR><BR>Contact Details: <BR>Address: VII/415 Nedumbassery, Athani P O Aluva Ernakulam Kerala : 683585 <BR>Tel: 91-484-2476301/2/3/4 <BR>Email: info@keralaayurveda.biz <BR>Website: http://www.keralaayurveda.biz

Has Kerala Ayurveda declared dividend?

No Dividend History Available

Who are the peers of the Kerala Ayurveda?

Kerala Ayurveda's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Ind-Swift Labs, Albert David, Medico Remedies, and Accent Microcell. While Kerala Ayurveda has below average management risk and growth, its 1-year return is 42.32%, higher than Ind-Swift Labs but lower than Divi's Lab's 51.69%.

Peers: The peers of Kerala Ayurveda are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Ind-Swift Labs., Albert David, Medico Remedies, Accent Microcell.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and the rest. Good management risk is found at Divi's Lab., Torrent Pharma, and the rest. Average management risk is present at Albert David, Medico Remedies, Accent Microcell, and the rest. Below average management risk is noted for Kerala Ayurveda and Ind-Swift Labs. Growth is excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while below average growth is seen in Kerala Ayurveda, Ind-Swift Labs., and Torrent Pharma. Average growth is found at Medico Remedies, and good growth is noted for Accent Microcell. Capital structure is excellent for Sun Pharma.Inds., Cipla, Divi's Lab., and Dr Reddy's Labs, while good capital structure is observed at Medico Remedies, and below average capital structure is noted for Kerala Ayurveda, Ind-Swift Labs., and Torrent Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.69%, while the lowest is Ind-Swift Labs. at -21.31%. Kerala Ayurveda's own 1-year return is 42.32%, which is significantly higher than Ind-Swift Labs. but lower than Divi's Lab. Additionally, peers with negative six-month returns include Ind-Swift Labs., Albert David, and Accent Microcell.

Is Kerala Ayurveda overvalued or undervalued?

As of May 27, 2025, Kerala Ayurveda is considered risky and overvalued with a PE ratio of -37.04 and an EV to EBITDA of -122.35, significantly lagging behind peers like Sun Pharma and Cipla, despite a strong 1-year stock return of 55.01% compared to the Sensex's 7.58%.

As of 27 May 2025, the valuation grade for Kerala Ayurveda has moved from very expensive to risky, indicating a significant shift in its market perception. The company appears to be overvalued, with a PE ratio of -37.04, an EV to EBITDA ratio of -122.35, and a Price to Book Value of 57.37. These ratios suggest that the company's earnings and asset valuations are not aligned with its current market price.<BR><BR>In comparison to its peers, Kerala Ayurveda's metrics are starkly unfavorable. For instance, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla shows a PE of 22.99 and an EV to EBITDA of 15.93, both indicating more robust valuations. The company's recent stock performance has outpaced the Sensex, with a 1-year return of 55.01% compared to the Sensex's 7.58%, but this does not mitigate its current overvaluation status.

Are Kerala Ayurveda latest results good or bad?

Kerala Ayurveda's latest results show a profit after tax of Rs 1.99 crore, a significant improvement from previous quarters, but rising interest expenses and reliance on non-operating income raise concerns about its financial stability. Analysts currently rate the stock as 'Sell', indicating caution about its future performance.

Kerala Ayurveda's latest financial results show a mixed picture. On one hand, the company reported a profit after tax (PAT) of Rs 1.99 crore for the quarter ending June 2025, which is a remarkable growth of 154.1% compared to the average PAT of Rs -3.68 crore over the previous four quarters. This indicates a significant improvement in profitability.<BR><BR>However, there are notable challenges as well. The company has seen a substantial increase in interest expenses, which rose to Rs 3.30 crore, reflecting a 186.96% increase compared to the previous half-year. This suggests that the company is facing difficulties in managing its debt. Additionally, the operating profit to interest ratio has dropped to its lowest point in five quarters at -5.11 times, indicating struggles with covering interest payments.<BR><BR>Moreover, a large portion of the profit before tax is coming from non-operating income, which constituted 337.01% of that figure, raising concerns about the sustainability of this income source. <BR><BR>Overall, while there are positive signs in terms of profitability, the rising interest expenses and reliance on non-operating income suggest that the company's financial health may be precarious. The stock is currently rated as 'Sell' by MarketsMOJO, reflecting caution among analysts regarding its future performance.

How big is Kerala Ayurveda?

As of 24th July, Kerala Ayurveda Ltd has a market capitalization of 673.00 Cr and reported Net Sales of 121.47 Cr with a Net Profit loss of 13.03 Cr over the latest four quarters. The balance sheet for March 2024 shows Shareholder's Funds of 32.16 Cr and Total Assets of 140.71 Cr.

As of 24th July, Kerala Ayurveda Ltd has a market capitalization of 673.00 Cr, classified as a Micro Cap.<BR><BR>In the latest four quarters, the company reported Net Sales of 121.47 Cr. However, it faced a loss of 13.03 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 32.16 Cr and Total Assets of 140.71 Cr.

Is Kerala Ayurveda technically bullish or bearish?

As of 29 October 2025, the market trend is neutral with mixed signals, showing a shift from mildly bullish to sideways, as weekly indicators are mostly bearish while monthly indicators remain bullish.

As of 29 October 2025, the technical trend has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed signals across different time frames. The weekly MACD is mildly bearish, while the monthly MACD remains bullish, indicating a divergence in momentum. The weekly Bollinger Bands are also mildly bearish, contrasting with the monthly Bollinger Bands which are mildly bullish. Moving averages on the daily chart show a mildly bullish stance, but the KST and Dow Theory are both bearish on the weekly and monthly charts. Overall, the indicators suggest a lack of clear direction, reinforcing the sideways trend.

When is the next results date for Kerala Ayurveda?

The next results date for Kerala Ayurveda is 14 November 2025.

The next results date for Kerala Ayurveda is scheduled for 14 November 2025.

How has been the historical performance of Kerala Ayurveda?

Kerala Ayurveda's historical performance has shown revenue growth from INR 58.90 crore in March 2019 to INR 120.33 crore in March 2025, but profitability has declined sharply, resulting in a net loss of INR -13.96 crore in March 2025. Despite positive cash flow from operations of INR 4.00 crore, the company faced significant challenges with an overall net cash outflow of INR -19.00 crore.

Answer:<BR>The historical performance of Kerala Ayurveda shows significant fluctuations over the years, particularly in revenue and profitability.<BR><BR>Breakdown:<BR>Kerala Ayurveda's net sales have shown a steady increase from INR 58.90 crore in March 2019 to INR 120.33 crore in March 2025. However, the total expenditure has also risen sharply, leading to an operating profit (PBDIT) that turned negative at INR -4.99 crore in March 2025, down from INR 8.83 crore in March 2024. This decline in profitability is reflected in the profit before tax, which fell to INR -12.24 crore in March 2025, compared to a profit of INR 0.66 crore in the previous year. Consequently, the profit after tax also dropped significantly to INR -13.96 crore in March 2025, indicating a challenging financial environment. The company's total assets decreased slightly to INR 123.99 crore in March 2025 from INR 128.47 crore in March 2024, while total liabilities also saw a decline to INR 123.99 crore from INR 128.47 crore. Cash flow from operating activities was positive at INR 4.00 crore in March 2025, but the overall net cash outflow was INR -19.00 crore, reflecting the company's struggles in managing its cash position effectively.

Should I buy, sell or hold Kerala Ayurveda?

Which are the latest news on Kerala Ayurveda?

Why is Kerala Ayurveda falling/rising?

As of 03-Dec, Kerala Ayurveda Ltd's stock price is at 357.00, reflecting a decline of 5.35 (-1.48%) and a significant drop of 12.38% over the last month. The stock is currently underperforming its sector and has seen reduced investor participation, indicating a lack of confidence.

As of 03-Dec, Kerala Ayurveda Ltd's stock price is falling, currently at 357.00, which reflects a decrease of 5.35 (-1.48%). The stock has been on a downward trend, having lost 7.34% over the last four days. Additionally, it has underperformed its sector by 1.47% today. <BR><BR>The stock's performance over various periods shows a significant decline, particularly in the last month with a drop of 12.38%, and a year-to-date decrease of 19.23%. Although it has shown a positive return of 10.24% over the past year and an impressive 321.99% over three years, the recent trends indicate a struggle to maintain momentum.<BR><BR>Today's trading activity further illustrates the stock's challenges, as it traded lower than all its moving averages (5-day, 20-day, 50-day, 100-day, and 200-day). The stock reached a high of Rs 376 but also fell to a low of Rs 348 during the day. Moreover, there has been a significant drop in investor participation, with delivery volume on December 2 falling by 78.49% compared to the 5-day average. This decline in trading activity suggests a lack of confidence among investors, contributing to the stock's falling price.